Chronic obstructive pulmonary disease

Pulmonx Announces that UnitedHealthcare, the Largest Commercial Insurer in the United States, Has Lifted Coverage Restrictions on the Zephyr Valve, a Minimally-Invasive Treatment Option for Severe Emphysema (COPD)

Monday, November 18, 2019 - 2:30pm

View the full release here: https://www.businesswire.com/news/home/20191118005502/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20191118005502/en/
    Pulmonx Announces that UnitedHealthcare, the Largest Commercial Insurer in the United States, Has Lifted Coverage Restrictions on the Zephyr Valve, a Minimally-Invasive Treatment Option for Severe Emphysema / COPD (Photo: Pulmonx Corporation)
    UnitedHealthcare is the largest commercial health insurer in the United States covering more than 44.8 million members.
  • As of October 1, 2019, UnitedHealthcare no longer considers endobronchial valve procedures unproven, when used in appropriate patients.
  • With these coverage updates, the Zephyr Valve is now an available treatment option for over 77 million Americans with commercial insurance.
  • Pulmonx Corporation is a medical device company that provides minimally-invasive solutions to treat patients with severe emphysema, a form of COPD.

H-CYTE Raises $6 Million to Accelerate FDA Approval Process of Next Generation Cellular Therapy for COPD

Monday, November 18, 2019 - 1:00pm

The new funding will be used to advance the companys development of industry-leading medical treatments for chronic lung diseases such as COPD.

Key Points: 
  • The new funding will be used to advance the companys development of industry-leading medical treatments for chronic lung diseases such as COPD.
  • It is estimated that 24 million people in the U.S. have COPD, an umbrella term that encompasses many other conditions, including emphysema and chronic bronchitis.
  • According to the CDC , more than 140,000 Americans die from this condition each year and there is currently no cure.
  • H-CYTE recently entered into a long-term agreement with Rion that will enable H-CYTE to develop proprietary biologics for treatment of COPD.

Fifth Season Financial Offers Resources for COPD Patients Facing Financial Hardship

Wednesday, November 13, 2019 - 5:27pm

Recognizing National COPD Awareness Month this November, specialty lender Fifth Season Financial has developed an online resource for patients as well as a solution to help alleviate the financial strain associated with COPD and other advanced-stage illnesses.

Key Points: 
  • Recognizing National COPD Awareness Month this November, specialty lender Fifth Season Financial has developed an online resource for patients as well as a solution to help alleviate the financial strain associated with COPD and other advanced-stage illnesses.
  • Fifth Season Financial's new blog post, Financial Solutions for Patients with Chronic Obstructive Pulmonary Disease (COPD) , includes information on programs available to help minimize patients' financial challenges.
  • "Coping with a serious illness can drain savings and rack up bills swiftly," said Fifth Season Financial president Adam Balinsky.
  • Fifth Season has provided over $190 million in financial assistance to more than 600 patients across the United States.

New Research Gives Hope for Slowing Progression and Mortality of Fourth Leading Cause of Death

Wednesday, November 13, 2019 - 1:30pm

Using the new criteria proposed in the published article would enable treatment to be provided earlier to slow or halt disease progression before disability or irreversible lung structural changes occurs.

Key Points: 
  • Using the new criteria proposed in the published article would enable treatment to be provided earlier to slow or halt disease progression before disability or irreversible lung structural changes occurs.
  • This new proposal comes from the COPD Genetic Epidemiology (COPDGene) studya 21-center study of 10,000 individuals supported by the National Institutes of Health and begun in 2007.
  • It may be decades before they actually meet GOLD criteria to be diagnosed with COPD.
  • If we diagnose earlier, we can provide better care and begin to focus on prevention, he explains.

Global Asthma Spacers Market 2019-2023 | Evolving Opportunities with ALLERGAN & Cipla | Technavio

Wednesday, November 13, 2019 - 11:30am

View the full release here: https://www.businesswire.com/news/home/20191113005363/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20191113005363/en/
    Technavio has announced its latest market research report titled global asthma spacers market 2019-2023.
  • Also, the increase in online retail is anticipated to further boost the growth of the asthma spacers market.
  • The growing demand for respiratory care is expected to drive the growth of the global asthma spacers market.
  • Allergy, pollution, and smoking can result in several respiratory diseases such as obstructive airway diseases like asthma, COPD, and cystic fibrosis.

The New 2020 Report from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Gives Highest Evidence Rating to Endobronchial Valves, including the Zephyr Valve, for Treatment of Emphysema / COPD

Monday, November 11, 2019 - 1:30pm

GOLD first added mention of the benefits of broncoscopic interventions for COPD, including endobronchial valves like the Zephyr Valve, in 2017.

Key Points: 
  • GOLD first added mention of the benefits of broncoscopic interventions for COPD, including endobronchial valves like the Zephyr Valve, in 2017.
  • The 2020 report upgrades endobronchial valves to the best evidence level available, making it the GOLD standard of care for qualifying patients.
  • With significant evidence now in place for endobronchial valve treatment, we can now offer patients a choice in treatment options.
  • Bronchoscopic lung volume reduction with the Zephyr Valve is a one-time procedure performed through a bronchoscope, which requires no cutting or incisions.

Global Anti-Asthmatics & COPD Drugs Market Report 2015-2019 & 2020-2030 - Industry Anticipated to Cross $42 Billion by 2022 - ResearchAndMarkets.com

Thursday, November 7, 2019 - 1:23pm

The global anti-asthmatics and COPD drugs market was valued at about $33.4 billion in 2018 and is expected to grow to $42.01 billion at a CAGR of 5.9% through 2022.

Key Points: 
  • The global anti-asthmatics and COPD drugs market was valued at about $33.4 billion in 2018 and is expected to grow to $42.01 billion at a CAGR of 5.9% through 2022.
  • Modifiable risk factors including smoking, lack of physical exercise, and unhealthy eating habits drive the Asthma and COPD drugs market.
  • Global Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
    4.3.
  • Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

New report highlights knowledge gaps in COPD - a disease that one million Canadians do not even know they have

Monday, October 28, 2019 - 11:00am

The results of the report were based on two Leger surveys one of Canadians living with COPD, and one of physicians.

Key Points: 
  • The results of the report were based on two Leger surveys one of Canadians living with COPD, and one of physicians.
  • The Human and Economic Burden of COPD: A Leading Cause of Hospital Admission in Canada https://www.lung.ca/file/309/download?token=KnAuJ7t7
    viiHelping the Missing Million Report on COPD.
  • COPD.
  • COPD.

Global Drug Delivery Inhalation Devices Market Report 2019: Market is Estimated to Reach $12.1 Billion in 2023

Friday, October 25, 2019 - 10:00pm

DUBLIN, Oct. 25, 2019 /PRNewswire/ -- The "Drug Delivery: Inhalation Devices" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 25, 2019 /PRNewswire/ -- The "Drug Delivery: Inhalation Devices" report has been added to ResearchAndMarkets.com's offering.
  • In 2018, combined sales of inhaled asthma and COPD devices in the countries covered by this analysis totalled approximately $10.4bn.
  • Over the forecast period covered by this analysis, total sales are expected to increase at a CAGR of 3.0%, reaching an estimated $12.1bn in 2023.
  • This report provides the following useful information:
    Top selling inhalation drug delivery devices, as well as emerging products under development
    In-depth market and competitive analyses.

Drug Delivery Inhalation Devices Market, 2023 - ResearchAndMarkets.com

Friday, October 25, 2019 - 2:01pm

The "Drug Delivery: Inhalation Devices" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Drug Delivery: Inhalation Devices" report has been added to ResearchAndMarkets.com's offering.
  • In 2018, combined sales of inhaled asthma and COPD devices in the countries covered by this analysis totalled approximately $10.4bn.
  • Medical devices covered by this analysis include metered dose inhalers (MDIs) and dry powder inhalers (DPIs) for the treatment of asthma and COPD.
  • This report provides the following useful information:
    Top selling inhalation drug delivery devices, as well as emerging products under development
    In-depth market and competitive analyses.